Biomimetic Therapeutics — Technical Presentation (June 2012)
26 slides from Biomimetic Therapeutics's technical presentation, Jun 21, 2012
Slide 1: Mandatory Disclosure Statement
Mandatory Disclosure Statement The following authors (or their immediate family members) have received something of value (≥ $500.00) from a commercial company or institution related directly or indirectly to the subject of this presentation, as noted below: a = research/institutional support, b = m
Slide 2: Outcomes of Hindfoot Fusions Augmented with Injectable Bone Graft
Inspiring Excellence R.J. Howard, MD, MBA President & CEO, St. Michael’s Hospital Outcomes of Hindfoot Fusions Augmented with Injectable Bone Graft Timothy Daniels , MD, FRCSC , Mark Glazebrook , MD , Alastair Younger , MD , Murray Penner , MD , Kevin Wing , MD , Ian Le , MD , Iain Russell, MD , Hug
Slide 3: Introduction
• Non - union rate for ankle/ hindfoot fusions is ~ 10% . 1 • High - risk populations (revisions, smokers, diabetics) - non - union rates 27 - 41% 2 - 3 • Continue to look at methods of improving union rates in ankle/ hindfoot fusions Introduction
Slide 4: recombinant Platelet Derived Growth Factor (rhPDGF-BB)
recombinant Platelet Derived Growth Factor ( rhPDGF - BB ) chemotactic proliferative angiogenic
Slide 5: Study Product
Study Product rhPDGF - BB solution (0.3 mg/ mL ) β - TCP/Type I collagen matrix Two Component Kit ( † Augment Injectable Bone Graft) † BioMimetic Therapeutics, Franklin, TN
Slide 6: Augment Injectable Bone Graft
Augment™ Injectable Bone Graft Ankle Fusion Surgery Tim Daniels, MD
Slide 7: Study Design
Study Design - Prospective, randomized, controlled, multi - center study - Procedure: Hindfoot or ankle fusion with internal fixation, supplemented with Augment™ Injectable Bone Graft
Slide 8: Study Design
Study Design - Randomization: 5:1 (Augment Injectable : Autograft ) - Statistical analysis plan specified utilization of control group from a prior study which utilized an identical protocol - F/U at 3, 6, 9, 12, 16, 24. 36 and 52wks - CT scans at 9, 16, 24, and 36 weeks - CT fusion assessed by a bl
Slide 9: Entry Criteria
Entry Criteria Key Inclusion Criteria » Research Ethics Board (REB) approved informed consent » Bone defect in foot/ankle fusion requiring bone graft » No more than 3 screws across the fusion site » ≥ 18 years of age Key Exclusion Criteria » Previous fusion or TAR surgery at fusion site » Plate fixa
Slide 10: Primary Endpoint
Primary Endpoint - Fusion on CT scan was defined as ≥ 50% osseous bridging, which has been described previously 2
Slide 11: Statistical Analysis Plan
Statistical Analysis Plan - Identical protocol and surgical technique - Robust autograft clinical database - No statistical differences between baseline study demographics when comparing both autograft groups - Prospective SAP specified utilization of autograft clinical database
Slide 12: Enrollment
Enrollment – 217 patients COFAS study group 63 (augment injectable ) 12 ( autograft ) 142 ( autograft – previous study 2006) 63 (augment injectable ) 154 ( autograft )
Slide 13: Patient Profile
Patient Profile Augment Injectable (N= 63) Autograft (N=154) Sex (M/F) 58.7%/ 41.3% 56.5% / 43.5% Age (Mean) 55.5 years 57.5 years BMI (Mean) 31.2 31.1 Diagnosis Post - traumatic injury/ deformity 57.1% 43.5% Primary Arthritis 30.1% 39.0% Rheumatoid 6.4% 5.1% Ot her 6.3% 12.3% Risk Factors Obesity (
Slide 14: Results: CT Fusion
Results: CT Fusion CT Scan (≥ 50% osseous bridging) Augment Injectable (N=63) Autograft (N=154) Non - Inferiority P - value Week 9 61.9% 40.3% < 0.001 Week 16 77.8% 59.1% < 0.001 Week 24 84.1% 64.9% < 0.001 Week 36 84.1% 71.4% < 0.001 Mean Time to Fusion (weeks) 14.3 19.7 < 0.001
Slide 15: Results: Clinical
Results: Clinical Augment Injectable (52 weeks) Autograft (52 weeks) Non - Inferiority p - value Subjects 63 154 Joints 81 230 Clinical Success 90.5% 77.9% <0.001 Clinical Healing 87.3% 87.7% 0.099 SF - 12 (PCS) 44.6 8.5 45.0 9.7 < 0.001
Slide 16: Results: Clinical
Results: Clinical Augment Injectable (52 weeks) Autograft (52 weeks) Non - Inferiority p - value Mean sd (N= 63) Mean sd (N=154) Foot Function Index 15.0 17.5 17.4 20.4 < 0.001 AOFAS Ankle - Hindfoot Scale 80.0 13.9 78.5 17.0 < 0.001 Fusion Site Pain 12.2 19.4 13.0 23.5 < 0.001 Weight Bearing Pain 1
Slide 17: Graft Harvest Site Pain
Graft Harvest Site Pain Augment Injectable (52 weeks) Autograft (52 weeks) Non - Inferiority p - value* % (N= 63) % (N=154) Clinically Significant Bone Graft Site Pain (≥20mm) 0 9 < 0.001 *p - value for superiority Chronic pain from bone graft surgical site
Slide 18: Safety Outcomes Summary
Safety Outcomes Summary Augment Injectable (N=63) Autograft (N=154) p - value* Subjects Events Subjects Events Related Treatment Emergent Adverse Events (TEAE) 2 (3.2%) 2 6 (3.9%) 10 >0.999 Serious AE 8 (12.7%) 9 23 (14.9%) 31 0.8313 *Two - tailed Fisher’s Exact p - value based on patient counts.
Slide 19: Case Report
Case Report (3. week post-op) St Michael's 7 esp
Slide 20: Case Report (9 week post-op CT scan)
Case Report ( 9 week post - op CT scan) Joint space shows evidence of early cross - trabeculation at 9 weeks
Slide 21: Case Report
Case Report ( 24 week post - op)
Slide 22: Case Report (24 week post-op CT scan)
Case Report (24 week post - op CT scan)
Slide 23: Case Report (36 week post-op CT scan)
Case Report (36 week post - op CT scan)
Slide 24: Conclusion
Conclusion » Augment Injectable Bone Graft has equivalent (i.e., non - inferior) outcomes to autologous graft » AIBG may have improved time to fusion rate relative to autograft (additional patients needed for definitive claim) » AIBG has improved handling and delivery characteristics relative to sta
Slide 25: References
References 1 Haddad et. al . “Intermediate and Long - Term Outcomes of Total Ankle Arthoplasty and Ankle Arthodesis .” JBJS 89:1899 - 1905, 2007. 2 Easley et. al. “Isolated Subtalar Arthrodesis .” JBJS 82A:613 - 624, 2000. 3 Frey et. al . “A Review of Ankle Arthrodesis : Predisposing Factors to Nonu
Slide 26: Thank you
Inspiring Excellence R.J. Howard, MD, MBA President & CEO, St. Michael’s Hospital Thank you
BioMimetic Therapeutics — Technical Presentation (June 2012) on 6ix